Eupraxia Pharmaceuticals (EPRX) Assets Average (2024 - 2026)

Eupraxia Pharmaceuticals (EPRX) has 3 years of Assets Average data on file, last reported at $115.8 million in Q1 2026.

• On a quarterly basis, Assets Average rose 260.73% year-over-year to $115.8 million in Q1 2026; TTM through Mar 2026 was $115.8 million, a 260.73% increase from a year earlier, with the FY2025 full-year figure at $60.5 million, up 119.34% from the prior year.
• Assets Average for Q1 2026 stood at $115.8 million, up from $89.2 million in the prior quarter.
• Over the last five years, Assets Average for EPRX reached as high as $115.8 million in Q1 2026 and fell as low as $17.7 million in Q3 2024.
• Historically, Assets Average has averaged $46.8 million across 3 years, with a median of $30.8 million in 2024.
• On a YoY basis, Assets Average climbed as much as 293.97% in 2025 and fell as far as 14.25% in 2025.
• Year by year, Assets Average stood at $22.7 million in 2024, then surged by 293.97% to $89.2 million in 2025, then gained by 29.69% to $115.8 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $115.8 million in Q1 2026, $89.2 million in Q4 2025, and $58.0 million in Q3 2025.